-+ 0.00%
-+ 0.00%
-+ 0.00%

Zejing Pharmaceutical (688266.SH): The marketing application for a new indication of injectable human thyrotropin beta was accepted

Zhitongcaijing·09/06/2026 07:41:06
Listen to the news

Zhitong Financial App News, Zejing Pharmaceutical (688266.SH) issued an announcement. Recently, the company received the “Notice of Acceptance” approved and issued by the State Drug Administration. The application submitted by the company for the marketing of injectable human thyrotropin beta (former name: injectable recombinant human thyroid-stimulating hormone, trademark: zesuning®) was accepted. The accepted indication is for treatment of patients with differentiated thyroid cancer without distant metastases to remove residual thyroid tissue after total thyroidectomy or total thyroidectomy.